{"count":23931,"next":"http://api.gregory-ms.com/articles/?page=1347","previous":"http://api.gregory-ms.com/articles/?page=1345","results":[{"article_id":384164,"title":"Motivation for Physical Activity in Adults With Multiple Sclerosis: A Self-determination Theory-Based Approach","summary":"CONCLUSIONS: Increasing satisfaction of the need for relatedness, competence, and autonomy can lead to more integrated and internally motivated PA engagement in adults with MS.","link":"https://pubmed.ncbi.nlm.nih.gov/35645627/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Consortium of Multiple Sclerosis Centers","container_title":"International Journal of MS Care","authors":[{"author_id":251804,"given_name":"Narissa","family_name":"McCarty","ORCID":null,"country":null},{"author_id":251805,"given_name":"Samantha","family_name":"Sayer","ORCID":null,"country":null},{"author_id":155010,"given_name":"Susan L.","family_name":"Kasser","ORCID":"http://orcid.org/0000-0001-7095-4414","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.766176Z","noun_phrases":["Motivation","Physical Activity","Adults","Multiple Sclerosis","A Self-determination Theory-Based Approach"],"doi":"10.7224/1537-2073.2020-091","access":"open","takeaways":"","categories":[]},{"article_id":384163,"title":"The Impact of COVID-19 on the Lives of Individuals With Multiple Sclerosis: 1 Year Into the Pandemic","summary":"CONCLUSIONS: During the first year of the pandemic, this study found no pronounced impact on the emotional, social, or economic stability of the individuals with MS it surveyed. It seems that these study participants adapted to the restrictions created by the pandemic and, by adhering to guidelines, protected themselves from contracting SARS-CoV-2.","link":"https://pubmed.ncbi.nlm.nih.gov/35645628/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Consortium of Multiple Sclerosis Centers","container_title":"International Journal of MS Care","authors":[{"author_id":236905,"given_name":"Sharon","family_name":"Lynch","ORCID":null,"country":null},{"author_id":207265,"given_name":"Sara","family_name":"Baker","ORCID":"http://orcid.org/0000-0003-0648-0191","country":null},{"author_id":299241,"given_name":"Suzanne","family_name":"Hunt","ORCID":null,"country":null},{"author_id":236907,"given_name":"Amanda","family_name":"Thuringer","ORCID":null,"country":null},{"author_id":299242,"given_name":"Yasir","family_name":"Jassam","ORCID":null,"country":null},{"author_id":236909,"given_name":"Jared","family_name":"Bruce","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.765335Z","noun_phrases":["The Impact","COVID-19","the Lives","Individuals","Multiple Sclerosis","1 Year","the Pandemic"],"doi":"10.7224/1537-2073.2021-099","access":"open","takeaways":" During the first year of the pandemic, this study found no pronounced impact on the emotional, social, or economic","categories":[]},{"article_id":384162,"title":"Self-reported Reasons for Changes in Performance of Daily Activities During a 2-Year Multidisciplinary Multiple Sclerosis Rehabilitation","summary":"CONCLUSIONS: The outpatient rehabilitation program, including 4 themes-cognition, mood, energy conservation, and body control-improved the self-reported performance of patients with MS with moderate and severe disabilities. Environmental factors warrant consideration during rehabilitation.","link":"https://pubmed.ncbi.nlm.nih.gov/35645629/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Consortium of Multiple Sclerosis Centers","container_title":"International Journal of MS Care","authors":[{"author_id":153908,"given_name":"Maarit E.","family_name":"Karhula","ORCID":"http://orcid.org/0000-0003-0464-202X","country":null},{"author_id":250480,"given_name":"Katja","family_name":"Kanelisto","ORCID":null,"country":null},{"author_id":177576,"given_name":"Päivi","family_name":"Hämäläinen","ORCID":"http://orcid.org/0000-0002-9020-4650","country":null},{"author_id":250484,"given_name":"Juhani","family_name":"Ruutiainen","ORCID":null,"country":null},{"author_id":250486,"given_name":"Pertti","family_name":"Era","ORCID":null,"country":null},{"author_id":250488,"given_name":"Arja","family_name":"Häkkinen","ORCID":null,"country":null},{"author_id":250490,"given_name":"Anna-Liisa","family_name":"Salminen","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.764674Z","noun_phrases":["Self-reported Reasons","Changes","Performance","Daily Activities","a 2-Year Multidisciplinary Multiple Sclerosis Rehabilitation"],"doi":"10.7224/1537-2073.2020-061","access":"open","takeaways":"","categories":[]},{"article_id":384161,"title":"Editorial: Autoimmunity and the Brain: Paraneoplastic Neurological Injury and Beyond","summary":null,"link":"https://pubmed.ncbi.nlm.nih.gov/35645953/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Neurology","authors":[{"author_id":333195,"given_name":"Ida","family_name":"Herdlevær","ORCID":"http://orcid.org/0000-0002-4146-7606","country":null},{"author_id":284794,"given_name":"John E.","family_name":"Greenlee","ORCID":null,"country":null},{"author_id":245746,"given_name":"Noel G.","family_name":"Carlson","ORCID":null,"country":null},{"author_id":155596,"given_name":"Justin R.","family_name":"Abbatemarco","ORCID":"http://orcid.org/0000-0003-1668-4753","country":null},{"author_id":200918,"given_name":"Stacey L.","family_name":"Clardy","ORCID":"http://orcid.org/0000-0001-6600-9428","country":null},{"author_id":284796,"given_name":"Christian A.","family_name":"Vedeler","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":null,"discovery_date":"2022-06-01T17:50:07.763974Z","noun_phrases":["Editorial","Autoimmunity","the Brain","Paraneoplastic Neurological Injury"],"doi":"10.3389/fneur.2022.900130","access":"open","takeaways":"","categories":[]},{"article_id":384160,"title":"Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the \"Attikon\" Lupus Cohort","summary":"CONCLUSIONS: Demyelination in the context of SLE follows a more benign course compared to a frank SLE-MS overlap. Extension of follow-up will ascertain whether patients with SLE-demyelination evolve to MS, or this is a bona fide NPSLE syndrome.","link":"https://pubmed.ncbi.nlm.nih.gov/35645967/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Neurology","authors":[{"author_id":278627,"given_name":"Dionysis","family_name":"Nikolopoulos","ORCID":null,"country":null},{"author_id":316060,"given_name":"Dimitrios","family_name":"Kitsos","ORCID":"http://orcid.org/0000-0003-0722-9329","country":null},{"author_id":278629,"given_name":"Matilda","family_name":"Papathanasiou","ORCID":null,"country":null},{"author_id":278630,"given_name":"Noemin","family_name":"Kapsala","ORCID":null,"country":null},{"author_id":278631,"given_name":"Panagiotis","family_name":"Garantziotis","ORCID":null,"country":null},{"author_id":278632,"given_name":"Antigone","family_name":"Pieta","ORCID":null,"country":null},{"author_id":278633,"given_name":"Ourania","family_name":"Gioti","ORCID":null,"country":null},{"author_id":278634,"given_name":"Alexandros","family_name":"Grivas","ORCID":null,"country":null},{"author_id":248680,"given_name":"Konstantinos","family_name":"Voumvourakis","ORCID":null,"country":null},{"author_id":278635,"given_name":"Dimitrios","family_name":"Boumpas","ORCID":null,"country":null},{"author_id":161416,"given_name":"Antonis","family_name":"Fanouriakis","ORCID":"http://orcid.org/0000-0003-2696-031X","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.763299Z","noun_phrases":["Demyelinating Syndromes","Systemic Lupus Erythematosus","Data","the \"Attikon\" Lupus Cohort"],"doi":"10.3389/fneur.2022.889613","access":"open","takeaways":"","categories":[]},{"article_id":384159,"title":"Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases","summary":"Cognitive impairment may be associated with aquaporin-4 antibody positive (AQP4+) NMOSD, particularly where there is prominent cerebral, corpus callosum, or thalamic involvement. It is unclear to what extent this phenomenon may be treatable after months to years. We describe two cases of AQP4+ NMOSD with cognitive impairment persisting over more than 6 months, where cognition improved after eculizumab was initiated. In the first case, a 51-year-old woman presented with a 2-month history of...","link":"https://pubmed.ncbi.nlm.nih.gov/35645973/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Neurology","authors":[{"author_id":254153,"given_name":"Georges","family_name":"Saab","ORCID":null,"country":null},{"author_id":254154,"given_name":"David G.","family_name":"Munoz","ORCID":null,"country":null},{"author_id":254155,"given_name":"Dalia L.","family_name":"Rotstein","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.762546Z","noun_phrases":["Chronic Cognitive Impairment","AQP4","NMOSD","Improvement","Cognition","Eculizumab","A Report","Two Cases"],"doi":"10.3389/fneur.2022.863151","access":"open","takeaways":" Cognitive impairment may be associated with aquaporin-4 antibody positive (AQP4+) NMOSD, particularly where there is prominent cerebral, corpus callos","categories":[]},{"article_id":384158,"title":"Total Dairy Consumption Is Not Associated With Likelihood of a First Clinical Diagnosis of Central Nervous System Demyelination","summary":"CONCLUSION: While total dairy consumption was not associated with FCD in this Australian case-control study, yogurt consumption was associated with reduced likelihood of FDE.","link":"https://pubmed.ncbi.nlm.nih.gov/35645978/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Neurology","authors":[{"author_id":295205,"given_name":"Dao Ying Rachel","family_name":"Dieu","ORCID":null,"country":null},{"author_id":158958,"given_name":"Eleanor","family_name":"Dunlop","ORCID":"http://orcid.org/0000-0002-9139-015X","country":null},{"author_id":191599,"given_name":"Alison","family_name":"Daly","ORCID":"http://orcid.org/0000-0002-4919-5932","country":null},{"author_id":286777,"given_name":"Robyn M.","family_name":"Lucas","ORCID":null,"country":null},{"author_id":158959,"given_name":"Yasmine","family_name":"Probst","ORCID":"http://orcid.org/0000-0002-1971-173X","country":"AU"},{"author_id":158967,"given_name":"Lucinda J.","family_name":"Black","ORCID":"http://orcid.org/0000-0003-4727-4773","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.761720Z","noun_phrases":["Total Dairy Consumption","Likelihood","a First Clinical Diagnosis","Central Nervous System Demyelination"],"doi":"10.3389/fneur.2022.888559","access":"open","takeaways":"","categories":[]},{"article_id":384157,"title":"RNA Helicases in Microsatellite Repeat Expansion Disorders and Neurodegeneration","summary":"Short repeated sequences of 3-6 nucleotides are causing a growing number of over 50 microsatellite expansion disorders, which mainly present with neurodegenerative features. Although considered rare diseases in relation to the relatively low number of cases, these primarily adult-onset conditions, often debilitating and fatal in absence of a cure, collectively pose a large burden on healthcare systems in an ageing world population. The pathological mechanisms driving disease onset are complex...","link":"https://pubmed.ncbi.nlm.nih.gov/35646086/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Genetics","authors":[{"author_id":267645,"given_name":"Lydia M.","family_name":"Castelli","ORCID":null,"country":null},{"author_id":287698,"given_name":"Bridget C.","family_name":"Benson","ORCID":null,"country":null},{"author_id":287699,"given_name":"Wan-Ping","family_name":"Huang","ORCID":null,"country":null},{"author_id":267650,"given_name":"Ya-Hui","family_name":"Lin","ORCID":null,"country":null},{"author_id":178793,"given_name":"Guillaume M.","family_name":"Hautbergue","ORCID":"http://orcid.org/0000-0002-1621-261X","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:07.760731Z","noun_phrases":["RNA Helicases","Microsatellite Repeat Expansion Disorders","Neurodegeneration"],"doi":"10.3389/fgene.2022.886563","access":"open","takeaways":" Short repeated sequences of 3-6 nucleotides are causing a growing number of over 50 microsatellite expansion disorders . These primarily adult-onset conditions,","categories":[]},{"article_id":384156,"title":"Sequence Determinants of TDP-43 Ribonucleoprotein Condensate Formation and Axonal Transport in Neurons","summary":"Mutations in TDP-43, a RNA-binding protein with multiple functions in RNA metabolism, cause amyotrophic lateral sclerosis (ALS), but it is uncertain how defects in RNA biology trigger motor neuron degeneration. TDP-43 is a major constituent of ribonucleoprotein (RNP) granules, phase separated biomolecular condensates that regulate RNA splicing, mRNA transport, and translation. ALS-associated TDP-43 mutations, most of which are found in the low complexity domain, promote aberrant liquid to solid...","link":"https://pubmed.ncbi.nlm.nih.gov/35646935/?fc=20210216052009&ff=20220601135006&v=2.17.6","published_date":"2022-06-01T10:00:00Z","source":"PubMed","publisher":"Frontiers Media SA","container_title":"Frontiers in Cell and Developmental Biology","authors":[{"author_id":241671,"given_name":"Sonali S.","family_name":"Vishal","ORCID":null,"country":null},{"author_id":241670,"given_name":"Denethi","family_name":"Wijegunawardana","ORCID":null,"country":null},{"author_id":260303,"given_name":"Muthu Raj","family_name":"Salaikumaran","ORCID":null,"country":null},{"author_id":241674,"given_name":"Pallavi P.","family_name":"Gopal","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T17:50:06.763775Z","noun_phrases":["Sequence Determinants","TDP-43 Ribonucleoprotein Condensate Formation","Axonal Transport","Neurons"],"doi":"10.3389/fcell.2022.876893","access":"open","takeaways":" TDP-43 is a RNA-binding protein with multiple functions in RNA metabolism . It is unknown how defects in RNA biology trigger motor neuron degeneration .","categories":[]},{"article_id":383040,"title":"Efficacy and safety of Gyejibokryeong-hwan (GBH) in major depressive disorder: study protocol for multicentre randomised controlled trial","summary":"Abstract\n Background\n Gyejibokryeong-hwan (GBH) is an herbal medicine composed of five herbs. It has been widely used to treat gynaecological diseases in traditional East Asian medicine. Recent animal studies suggest antidepressant effects of GBH. In this trial, we explore the efficacy and safety of GBH in patients with major depressive disorder and to identify the optimal dose for the next phase III trial.\n \n Methods\n This trial will enrol 126 patients diagnosed with major depressive disorder and not treated with antidepressants. Participants will be randomised to receive a high or a low dose of GBH or placebo granules. The study drugs will be administered three times a day, for 8 weeks. The 17-item Hamilton Depression Rating Scale (HDRS) will be used to measure the severity of depressive symptoms at weeks 2, 4, 6, 8, and 12. The primary efficacy endpoint is the change from baseline in HDRS-17 total score post-treatment at week 8. Analysis of covariance will be based on the baseline HDRS-17 total score and site as the covariates. Safety assessment will be based on the frequency of adverse events. The severity and causality of the study drug will be assessed.\n \n Discussion\n This study is designed to evaluate the efficacy and safety of GBH granules compared with placebo in patients with major depressive disorder.\n \n Trial registration\n Clinical Research Information Service KCT0004417. Registered on November 1, 2019 (prospective registration)\n ","link":"https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06339-0","published_date":"2022-05-31T23:00:00Z","source":"BioMedCentral","publisher":"Springer Science and Business Media LLC","container_title":"Trials","authors":[{"author_id":304700,"given_name":"Yujin","family_name":"Choi","ORCID":null,"country":null},{"author_id":304701,"given_name":"In Chul","family_name":"Jung","ORCID":null,"country":null},{"author_id":304702,"given_name":"Ju Yeon","family_name":"Kim","ORCID":null,"country":null},{"author_id":304703,"given_name":"Seung-Hun","family_name":"Cho","ORCID":null,"country":null},{"author_id":323623,"given_name":"Yunna","family_name":"Kim","ORCID":"http://orcid.org/0000-0003-2286-1242","country":"KR"},{"author_id":304705,"given_name":"Sun-Yong","family_name":"Chung","ORCID":null,"country":null},{"author_id":304706,"given_name":"Hui-Yong","family_name":"Kwak","ORCID":null,"country":null},{"author_id":304707,"given_name":"Doo Suk","family_name":"Lee","ORCID":null,"country":null},{"author_id":304708,"given_name":"Wonwoo","family_name":"Lee","ORCID":null,"country":null},{"author_id":304709,"given_name":"In-Jeong","family_name":"Nam","ORCID":null,"country":null},{"author_id":219892,"given_name":"Changsop","family_name":"Yang","ORCID":"http://orcid.org/0000-0003-1277-3329","country":null},{"author_id":304710,"given_name":"Mi Young","family_name":"Lee","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2022-06-01T14:04:46.132663Z","noun_phrases":["Efficacy","safety","Gyejibokryeong-hwan","GBH","major depressive disorder","study protocol","multicentre","controlled trial"],"doi":"10.1186/s13063-022-06339-0","access":"open","takeaways":" Gyejibokryeong-hwan (GBH) is an herbal medicine composed of five herbs . It has been widely used to treat gynaecological diseases in traditional East Asian medicine . In this trial, we explore the efficacy and safety of GBH in patients with major depressive disorder .","categories":[]}]}